The FDA has cleared Kleo Pharmaceuticals' investigational new drug application for its candidate KP1237, combined with autologous natural killer cells, as a treatment for multiple myeloma in patients who have already undergone hematopoietic stem cell transplantation. The clearance allows Kleo to advance its planned trial, with enrollment slated to start in the first half of this year and topline data expected by the second half of 2021.
FDA clears IND for Kleo's multiple myeloma combo drug
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.